Vulvar Langerhans cell histiocytosis and thalidomide: an effective treatment option

Int J Dermatol. 2017 Mar;56(3):324-326. doi: 10.1111/ijd.13377. Epub 2016 Oct 25.

Authors

Julieta Ruiz Beguerie^{1

2}, Julia Fernández¹, Matías F Stringa¹, Javier Anaya^{1

3}

Affiliations

¹ Department of Dermatology, Austral University Hospital, Austral University, Buenos Aires, Argentina.
² Research Committee, Austral University Hospital, Austral University, Buenos Aires, Argentina.
³ Department of Pathology, Austral University Hospital, Austral University, Buenos Aires, Argentina.

PMID: 27778317
DOI: 10.1111/ijd.13377

No abstract available

Publication types

Case Reports

MeSH terms

Female
Histiocytosis, Langerhans-Cell / complications
Histiocytosis, Langerhans-Cell / drug therapy*
Humans
Immunosuppressive Agents / therapeutic use*
Middle Aged
Thalidomide / therapeutic use*
Vulvar Diseases / drug therapy*
Vulvar Diseases / etiology

Substances

Immunosuppressive Agents
Thalidomide